Darwin Knows

Home | Coverage | Agents | Pulse | LogIn | 


Merck KGaA

Darwin Score+2
TickerMRK
Latest Price111.25 EUR as of close on 04-Jul-2025
3 Month price range108.89 to 126.25 EUR
Market Capitalisation48.13Bn EUR
CountryGermany
RegionEurope
Economic SectorHealth Care
Business SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryPharmaceuticals
Sub-IndustryPharmaceuticals
Description
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
See More ...
Company URLhttps://www.merckgroup.com/en
See Darwins Full Analysis for Merck KGaA

Tell Me About

Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Merck KGaA. Further information and full detail is available when you login.

TMA PartFocus of AnalysisTMA Score
PriceAnalysis of performance, trend, RSI, OBV and moving averages-4
SentimentNews and Candle Patterns. +1
FundamentalsAnalyst Ratings, Valuation and Dividend analysis.0
FlowInstitutional, Fund and Insider buying and selling.0
ModelsForecast models.+5

Alerts

There are 5 live alerts for Merck KGaA.


Peer Comparison

There are 3 peers of Merck KGaA.
Asset NameIndustry GroupPerf(20d)%Asset Score
Bayer AG (BAYN)Pharmaceuticals-1.4-12
Dermapharm Holding SE (DMP)Pharmaceuticals-2.3+21
Evotec SE (EVT)Pharmaceuticals+2.1+11

Share Share on Facebook Share on Twitter Share on Threads Share on LinkedIn


To see complete information on Merck KGaA or any other assets please login.


If you do not already have an account you can register for a free trial of our service. This will let you explore all the analytical information we have on price, fundamantals, flow, sentiments & models for all the stocks under coverage. You will then be able to compare asset scores and perform a wide range of multi asset analysis such as Market Cycles and Relative Scores.


Follow Us Followon Twitter Share on LinkedIn

©2025 Darwin Knows - All Rights Reserved